Opus Genetics doses first patient in phase 1/2 clinical trial, BIRD-1, evaluating OPGx-BEST1 Opus Genetics’ BIRD-1 trial explores OPGx-BEST1 gene therapy for Best disease, focusing on safety, tolerability, and preliminary efficacy in retinal … Read More at Source. Author: Pumilo Share this: Click to share on X (Opens in new window) X Click to share on Facebook (Opens in new window) Facebook More Click to share on LinkedIn (Opens in new window) LinkedIn Click to share on Reddit (Opens in new window) Reddit Click to share on Tumblr (Opens in new window) Tumblr Click to share on Pinterest (Opens in new window) Pinterest Click to share on Pocket (Opens in new window) Pocket Click to share on Telegram (Opens in new window) Telegram Click to share on WhatsApp (Opens in new window) WhatsApp Like this:Like Loading... Related Tags: BirdNews November 17, 2025 by Pumilo Bird News 0
